PHP67 Economic Impact of Drugs De-Funding and Pharmaceutical Co-Payment  by Buigues-Pastor, L. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A415
Region to legislate on the matter, supporting the prescription of the biosimilar to the 
naive patient. The aim of this study was to evaluate the impact of cost-containment 
policies about biosimilars in Campania between 2009 and 2013. Methods: IMS 
Health regional database was used to carry out this descriptive retrospective drug-
utilization for the years 2009 through 2013. Information was retrieved about differ-
ent distribution channels (retail, direct distribution, hospital). Consumptions are 
expressed in Counting Units (CU) and trends have been calculated using Compound 
Average Grow Rate (CAGR). Results: In 2013, a total consumption of 930.859 CU of 
biosimilar drugs was registered in Italy (CAGR 13/09 68,8%). The penetration rate of 
biosimilar was 23,9% with regard to expenditure and 25,3% with regard to consump-
tion. Analyzing the consumption of biosimilars by therapeutic category in Italy, 
the consumption of erythropoietin and filgrastim has an index of annual growth 
respectively equal to 153.4% and 174.7%. In Campania, the penetration rate of all 
biosimilars was 31.4% of total expenditure and 35.9% of consumption. Analyzing 
the trend in consumption for single therapeutic category, it can be seen that pen-
etration is due to erythropoietin (297.5% CAGR); with regard to filgrastim, however, 
the average annual growth rate is around 54%. ConClusions: The results suggest 
that Campania Region records an index of market penetration of biosimilars higher 
than the national. This trend could be attributable to the cost-containment policies 
implemented in the region.
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objeCtives: to assess the consequences in terms of outpatient pharmaceutical 
expenditure, that accounted for changes in state law on de-funding of medicines 
and the introduction of pharmaceutical co-payment in 2012 in Spain. Methods: 
Cross-sectional study during 2012. Two health regions of Spain (Comunitat Valenciana 
with 5,129,266 inhabitants and Extremadura with 1,108,130. Total population: 
6,237,396) where analysed to determine the evolution of outpatient pharmaceuti-
cal expenditure after a change in state law (July 1,2012). We compared the first over 
the second half of 2012 by age and gender distinction. Results: The total spending 
was reduced by 16.80% after the new law. By gender, the reduction was greater in 
women (17.47% versus 15.25%). By age, the decrease was seen most sharply in the 
stretch of paediatrics (0 to 14 years). In older people, the stretch mostly affected 
was the one from 66 to 70 years old. The stretches with fewer changes in terms of 
outpatient pharmaceutical expenditure were 21-25 years (reduced by 5.42%) and 
46-50 years (reduced by 6.07%). ConClusions: After the de-funding of 400 drugs 
and the increase of pharmaceutical co-payment (40% previously and now variable, 
40%, 50% and 60% depending on income levels), a drastic drop in the amount of 
pharmaceutical outpatient expenditure is observed. Further analysis is required 
in order to assess whether that decline is sustained over time or, on the contrary, a 
new phase of positive growth begins.
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objeCtives: The Food and Drug Administration (FDA) issued a safety announce-
ment on January 10,2013 requiring manufacturers to lower the recommended dose 
of zolpidem for women. Lower dose recommendations for elderly patients were 
already labeled. This analysis describes the impact of the FDA safety announcement 
on the initial dose dispensed to new zolpidem users. Methods: Patients > = 18 
years old with an immediate- (IR) or extended-release (ER) zolpidem prescription 
between July 2012 and July 2013 were evaluated using MarketScan Commercial 
and Medicare Supplemental Databases. The first zolpidem prescription during the 
pre-warning (July 1, 2012 – Jan. 9, 2013) and post-warning (Jan. 10, 2012 – July 31, 2013) 
time periods was evaluated. Chi square tests were used to examine differences in 
the proportion of new users dispensed low dose zolpidem during each of the time 
periods. Results: Overall a significantly higher proportion of patients in all age 
gender groups received low dose IR zolpidem during the post-warning compared 
to the pre-warning period. Similar results were found for the ER formulation except 
among males 65 years or older. Before and after the FDA safety warning, the high-
est proportion of patients receiving low dose zolpidem (any formulation) for their 
first prescription was among elderly women (46% pre-warning; 53% post-warning). 
Even after the FDA warning, a large proportion of women 18 to 64 years old (63% IR; 
65% ER) and women 65 years or older (46% IR, 55% ER) received high dose zolpidem 
for their first prescription. ConClusions: For all age and gender categories, the 
proportion of patients receiving low dose zolpidem increased after the FDA safety 
warning issued in 2013. The highest proportion of low dose zolpidem use was seen 
in elderly females. However, the proportion of women and elderly who received low 
dose zolpidem even after the FDA safety warning was still relatively low.
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objeCtives: Medications in households offer a variety of opportunities for irra-
tional consumption and development of adverse drug reactions (ADR). One of the 
medicines most commonly associated with ADR are non-steroidal anti-inflam-
matory drugs (NSAIDs), one of the most frequently used medications in Serbia. 
Therefore, the aim of this study was to analyze the amount and structure of 
previous and current policies and regulations in the grey literature was conducted 
for this research. Results: 17 articles were included in the systematic review. The 
three most crucial issues in the regulatory process have been analyzed in detail 
and relate to products technical requirements, the type test report and the clinical 
trials evaluation. Concerning the ‘products technical requirements’ and the ‘type 
test report’, the main challenges are related to the lack of sufficient legal status 
and openness for interpretation. A new Regulation governing the Supervision and 
Administration of medical devices introduced in June 2014 now includes improve-
ments regarding specification of requirements. In addition, if a medical device ful-
fills certain requirements, it should be exempted from clinical trials, which signifies 
a major simplification for manufacturers. ConClusions: Getting a medical device 
registration certificate in China is a complicated, time-consuming process. The new 
regulatory policies in place focus more strongly on the clinical effectiveness and 
safety of medical devices. However, some major structural problems remain, i. e. 
the lack of technical standards for manufacturers, with major policy planning and 
changes currently underway in order to address these problems.
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objeCtives: The Medical Technologies Evaluation Programme (MTEP) was set up 
by NICE in 2009 to identify new medical devices and diagnostics that could improve 
patient experience and outcomes whilst driving health care efficiencies. Innovative 
products are submitted by manufacturers for evaluation, requiring confidence in 
the programme and its methods. The purpose of the study was to examine the 
experiences of manufacturers whose products have been assessed by MTEP, to 
review the challenges of the submission process, the resources required for the 
submission, NICE support for further evidence generation, and the impact of NICE 
recommendations on product uptake in the UK and elsewhere. Methods: A sys-
tematic review of published literature on MTEP and products/companies that have 
been through this process was completed. Qualitative interviews were then under-
taken with a representative sample of senior team members from manufacturers 
whose products have undergone MTEP review to elicit insight on their perceptions 
and experiences of the programme. Findings were collated and analysed themati-
cally. Results: Manufacturers have identified the benefits of submitting to MTEP 
in terms of value communication in the NHS, however key issues are: the signifi-
cant time and resource burden of completing the submission, the lack of funding 
for additional data generation where this is required, the challenges of adhering 
to the stringent timescale, and the questionable benefits of submitting for larger 
companies with extensive sales teams. There is also a recognised need for greater 
efforts to influence practice and prescribing decisions in the NHS based on the MTEP 
guidance. ConClusions: Manufacturer experience of the MTEP process is largely 
positive, however as MTEP is dependent on manufacturers to initiate submissions, 
key actions can be taken to incentivise future submissions. Priorities will be ensur-
ing that MTEP recommendations have a tangible and proven impact on prescribing 
decisions and that support is available for the submission development.
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objeCtives: Risk sharing agreements are among the new trends in pharmaceutical 
sector as a tool for reducing the drug expenditures and increasing patient access 
to innovative drugs. The objective of this study is to elaborate the availability of 
risk sharing agreements in the Turkish pharmaceutical sector. Methods: A lit-
erature review was undertaken to identify the existing risk sharing schemes in the 
European countries using “risk sharing agreements”, and risk sharing schemes” as 
key words. Results: Risk sharing agreements are mainly classified as financial 
based and performance based schemes. The vast majority of those agreements are 
implemented in oncology area, others are mostly implemented in ophthalmology, 
blood diseases and multiple sclerosis areas. Countries mostly prefer financial based 
schemes as they are easier to implement and track. Performance based agreements 
are relatively rare as they are more complicated due to the long length of follow up, 
lack of reliability of data generation/registration, administrative burden for all stake-
holders. ConClusions: Taking into account that original drugs to be reimbursed 
in Turkey need to grant a compulsory statutory discount which is generally 41%, 
it can be stated that Turkey is already implementing a financial based scheme. On 
the other hand, when availability of performance based risk sharing agreements is 
assessed, there is a lack of infrastructure to track drugs or non-responders and also 
it seems to be difficult to make this kind of agreements in Turkey without making 
any amendments in current regulations. In addition to these regulation issues, 
transaction and administrative costs should also be taken into account. On the 
other hand despite these difficulties, these schemes could provide budget control 
and patient access to highly innovative and expensive treatments.
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objeCtives: The expiration of biotech drugs patents has led to the creation of 
drugs copies of originator products, defined biosimilars. The automatic substitut-
ability between the originator and the biosimilar is not allowed in Europe with the 
exception of France. In Italy, in the absence of a national legislation, some Regions 
have issued directives to the spread of the biosimilar use. Campania was the first 
